Seeking Alpha

Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite SUPN)...

Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs